PMID- 2123888
OWN - NLM
STAT- MEDLINE
DCOM- 19910122
LR  - 20181113
IS  - 0021-9738 (Print)
IS  - 0021-9738 (Linking)
VI  - 86
IP  - 6
DP  - 1990 Dec
TI  - Tumor necrosis factor-alpha inhibits expression of pulmonary surfactant protein.
PG  - 1954-60
AB  - Tumor necrosis factor-alpha (TNF-alpha) decreased the expression of pulmonary 
      surfactant proteins SP-A and SP-B in human pulmonary adenocarcinoma cell lines. 
      The effect of TNF alpha on SP-A content and mRNA in the pulmonary adenocarcinoma 
      cell line, H441-4, was concentration and time dependent. TNF alpha decreased the 
      cellular content of SP-A to less than 10% of control 48 h after addition. TNF 
      alpha decreased de novo synthesis of SP-A and decreased the accumulation of SP-A 
      in media. SP-A mRNA was decreased within 12 h of addition of TNF alpha, with 
      nearly complete loss of SP-A mRNA observed after 24 h. Inhibitory effects of TNF 
      alpha on SP-A mRNA were dose-related with nearly complete inhibition of SP-A mRNA 
      caused by 25 ng/ml TNF alpha. The effects of TNF alpha on SP-A were distinct from 
      the effects of interferon gamma which increased SP-A content approximately 
      twofold in H441-4 cells. TNF alpha also decreased the content of SP-B mRNA. In 
      contrast to the inhibitory effect of TNF alpha on SP-A and SP-B mRNA, TNF alpha 
      increased mRNA encoding human manganese superoxide dismutase (Mn-SOD). TNF alpha 
      did not inhibit growth, alter cell viability or beta-actin mRNA in either cell 
      line. These in vitro studies demonstrate the marked pretranslational inhibitory 
      effects of the cytokine, TNF alpha, on the expression of pulmonary surfactant 
      proteins, SP-A and SP-B. The results support the concept that macrophage-derived 
      cytokines may control surfactant protein expression.
FAU - Wispe, J R
AU  - Wispe JR
AD  - University of Cincinnati, Department of Pediatrics, Ohio 45267-0541.
FAU - Clark, J C
AU  - Clark JC
FAU - Warner, B B
AU  - Warner BB
FAU - Fajardo, D
AU  - Fajardo D
FAU - Hull, W E
AU  - Hull WE
FAU - Holtzman, R B
AU  - Holtzman RB
FAU - Whitsett, J A
AU  - Whitsett JA
LA  - eng
GR  - HL-28623/HL/NHLBI NIH HHS/United States
GR  - HL-39605/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
RN  - 0 (Proteolipids)
RN  - 0 (Pulmonary Surfactant-Associated Protein A)
RN  - 0 (Pulmonary Surfactant-Associated Proteins)
RN  - 0 (Pulmonary Surfactants)
RN  - 0 (RNA, Messenger)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 82115-62-6 (Interferon-gamma)
RN  - EC 1.15.1.1 (Superoxide Dismutase)
SB  - IM
MH  - Blotting, Northern
MH  - Epithelium/metabolism
MH  - Gene Expression/drug effects
MH  - Humans
MH  - In Vitro Techniques
MH  - Interferon-gamma/pharmacology
MH  - Lung/cytology/*metabolism
MH  - Proteolipids/genetics/*metabolism
MH  - Pulmonary Surfactant-Associated Protein A
MH  - Pulmonary Surfactant-Associated Proteins
MH  - Pulmonary Surfactants/genetics/*metabolism
MH  - RNA, Messenger/genetics
MH  - Superoxide Dismutase/genetics
MH  - Tumor Cells, Cultured
MH  - Tumor Necrosis Factor-alpha/*pharmacology
PMC - PMC329831
EDAT- 1990/12/01 00:00
MHDA- 1990/12/01 00:01
PMCR- 1990/12/01
CRDT- 1990/12/01 00:00
PHST- 1990/12/01 00:00 [pubmed]
PHST- 1990/12/01 00:01 [medline]
PHST- 1990/12/01 00:00 [entrez]
PHST- 1990/12/01 00:00 [pmc-release]
AID - 10.1172/JCI114929 [doi]
PST - ppublish
SO  - J Clin Invest. 1990 Dec;86(6):1954-60. doi: 10.1172/JCI114929.